Salvetero Therapeutics secures £383.5k for biotechnology research

Developing new techniques in gene and RNA vectors is a core focus for Salvetero Therapeutics Ltd, which recently secured an estimated £383.5k investment. This funding round values the London-based biotechnology company at approximately £2.5m. The firm specializes in research and experimental development across several high-tech disciplines, including nanobiotechnology and cell and tissue culture.

The startup, which was incorporated in July, also conducts biology research and works with DNA/RNA. Its technical scope extends to the engineering of biological materials, the use of bioinformatics, and the application of process biotechnology techniques for experimental purposes.

Manish Tandon joined the company as a director in July. While his specific role is unconfirmed, AI-derived matching suggests he may be an investor, advisor, or CEO. Formal documentation for this funding round was filed in August (with the allotment also occurring in August).